Hepatitis Monthly

Published by: Kowsar

Association of Tumor Necrosis Factor-alpha Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease

Yuting Cheng 1 , Baiquan An 1 , Man Jiang 2 , Yongning Xin 2 , * and Shiying Xuan 1
Authors Information
1 Department of Gastroenterology, Qingdao Medical College; Nanjing Medical University, Qingdao, China
2 Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao Medical College, Nanjing Medical University, Qingdao, China
Article information
  • Hepatitis Monthly: March 01, 2015, 15 (3); e26818
  • Published Online: March 31, 2015
  • Article Type: Research Article
  • Received: January 14, 2015
  • Revised: February 2, 2015
  • Accepted: February 14, 2015
  • DOI: 10.5812/hepatmon.26818

To Cite: Cheng Y, An B, Jiang M, Xin Y, Xuan S. et al. Association of Tumor Necrosis Factor-alpha Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease, Hepat Mon. 2015 ;15(3):e26818. doi: 10.5812/hepatmon.26818.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6): 1387-95[DOI][PubMed]
  • 2. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011; 26 Suppl 1: 163-72[DOI][PubMed]
  • 3. Abangah G, Yousefi A, Asadollahi R, Veisani Y, Rahimifar P, Alizadeh S. Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. Iran Red Crescent Med J. 2014; 16(1)[DOI][PubMed]
  • 4. Jafarian A, Ebrahimi A, Azmoudeh Ardalan F, Dashti H, Rahimi M, Salehi M, et al. NAFLD Prevalence in a Young Cadaveric Organ Donor Population. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 5. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. 2011; 17(26): 3082-91[DOI][PubMed]
  • 6. Bieghs V, Rensen PC, Hofker MH, Shiri-Sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis. 2012; 220(2): 287-93[DOI][PubMed]
  • 7. Sookoian S, Gianotti TF, Rosselli MS, Burgueno AL, Castano GO, Pirola CJ. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis. 2011; 218(2): 378-85[DOI][PubMed]
  • 8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363(14): 1341-50[DOI][PubMed]
  • 9. Zhang H, Chen L, Xin Y, Lou Y, Liu Y, Xuan S. Apolipoprotein c3 gene polymorphisms are not a risk factor for developing non-alcoholic Fatty liver disease: a meta-analysis. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 10. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271(5249): 665-8[PubMed]
  • 11. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999; 18(6): 353-8[DOI][PubMed]
  • 12. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999; 84(5): 1513-7[DOI][PubMed]
  • 13. Balci SO, Col-Araz N, Baspinar O, Sever T, Balat A, Pehlivan S. Cytokine Gene Polymorphisms in Childhood Dilated Cardiomyopathy: Interferon- gamma, Tumor Necrosis Factor-alpha and Transforming Growth Factor - beta 1 Genes Are Associated with the Disease in Turkish Patients. Iran J Pediatr. 2013; 23(5): 603-4[PubMed]
  • 14. Boehm J, Hauner K, Grammer J, Dietrich W, Wagenpfeil S, Braun S, et al. Tumor necrosis factor-alpha -863 C/A promoter polymorphism affects the inflammatory response after cardiac surgery. Eur J Cardiothorac Surg. 2011; 40(1)-4[DOI][PubMed]
  • 15. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun. 2004; 5(5): 315-29[DOI][PubMed]
  • 16. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009; 1792(3): 163-72[PubMed]
  • 17. Anoosheh S, Farnia P, Kargar M. Association between TNF-Alpha (-857) Gene Polymorphism and Susceptibility to Tuberculosis. Iran Red Crescent Med J. 2011; 13(4): 243-8[PubMed]
  • 18. Naderi M, Yaghootkar H, Tara F, Tavakkol Afshari J, Farid Hosseini R, Ghayour Mobarhan M, et al. Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia. Iran Red Crescent Med J. 2014; 16(1)[DOI][PubMed]
  • 19. Hu ZW, Luo HB, Xu YM, Guo JW, Deng XL, Tong YW, et al. Tumor necrosis factor--alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol Belg. 2009; 72(2): 215-21[PubMed]
  • 20. Huang J, Li YY, Zhou YJ. [Association between tumor necrosis factor-alpha gene polymorphism and insulin resistance in nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2006; 14(8): 613-5[PubMed]
  • 21. Zhou YJ, Li YY, Nie YQ, Yang H, Zhan Q, Huang J, et al. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol. 2010; 25(4): 772-7[DOI][PubMed]
  • 22. Wang JK, Feng ZW, Li YC, Li QY, Tao XY. Association of tumor necrosis factor-alpha gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol. 2012; 27(4): 670-6[DOI][PubMed]
  • 23. Yamada Y, Ichihara S, Izawa H, Tanaka M, Yokota M. Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Mol Genet Metab. 2004; 81(4): 282-90[DOI][PubMed]
  • 24. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol. 2007; 46(6): 1104-10[DOI][PubMed]
  • 25. Cho HC, Yu G, Lee MY, Kim HS, Shin DH, Kim YN. TNF-alpha polymorphisms and coronary artery disease: association study in the Korean population. Cytokine. 2013; 62(1): 104-9[DOI][PubMed]
  • 26. Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, et al. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis. 2003; 167(2): 257-64[PubMed]
  • 27. Allen RA, Lee EM, Roberts DH, Park BK, Pirmohamed M. Polymorphisms in the TNF-alpha and TNF-receptor genes in patients with coronary artery disease. Eur J Clin Invest. 2001; 31(10): 843-51[PubMed]
  • 28. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest. 1998; 28(1): 59-66[PubMed]
  • 29. Wang XL, Oosterhof J. Tumour necrosis factor alpha G-308-->A polymorphism and risk for coronary artery disease. Clin Sci (Lond). 2000; 98(4): 435-7[PubMed]
  • 30. Keso T, Perola M, Laippala P, Ilveskoski E, Kunnas TA, Mikkelsson J, et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis. 2001; 154(3): 691-7[PubMed]
  • 31. Chu H, Yang J, Mi S, Bhuyan SS, Li J, Zhong L, et al. Tumor necrosis factor-alpha G-308 A polymorphism and risk of coronary heart disease and myocardial infarction: A case-control study and meta-analysis. J Cardiovasc Dis Res. 2012; 3(2): 84-90[DOI][PubMed]
  • 32. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964; 2(5402): 177[PubMed]
  • 33. Jian-gao F, Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010; 18(3): 163-6[PubMed]
  • 34. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007; 92(9): 3490-7[DOI][PubMed]
  • 35. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992; 10: 411-52[DOI][PubMed]
  • 36. Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J Investig Med. 1995; 43(3): 227-35[PubMed]
  • 37. Shin KC, Chung JH, Lee KH. Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. Korean J Intern Med. 2007; 22(4): 249-55[PubMed]
  • 38. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology. 1989; 124(5): 2336-42[DOI][PubMed]
  • 39. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992; 41 Suppl 2: 97-101[PubMed]
  • 40. Morin CL, Schlaepfer IR, Eckel RH. Tumor necrosis factor-alpha eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes. J Clin Invest. 1995; 95(4): 1684-9[DOI][PubMed]
  • 41. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002; 122(2): 274-80[PubMed]
  • 42. Park SH, Koo HJ, Sung YY, Kim HK. The protective effect of Prunella vulgaris ethanol extract against vascular inflammation in TNF-alpha-stimulated human aortic smooth muscle cells. BMB Rep. 2013; 46(7): 352-7[PubMed]
  • 43. Savic-Radojevic A, Radovanovic S, Pekmezovic T, Pljesa-Ercegovac M, Simic D, Djukic T, et al. The role of serum VCAM-1 and TNF-alpha as predictors of mortality and morbidity in patients with chronic heart failure. J Clin Lab Anal. 2013; 27(2): 105-12[DOI][PubMed]
  • 44. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens. 2012; 25(6): 644-50[DOI][PubMed]
  • 45. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(5): 513-20[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments